Institution
University of Texas Health Science Center at San Antonio
Education•San Antonio, Texas, United States•
About: University of Texas Health Science Center at San Antonio is a education organization based out in San Antonio, Texas, United States. It is known for research contribution in the topics: Population & Melatonin. The organization has 28008 authors who have published 44104 publications receiving 2281613 citations. The organization is also known as: UT Health San Antonio.
Topics: Population, Melatonin, Cancer, Diabetes mellitus, Insulin
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Its pathogenesis varies based on the underlying etiological factor although majority of cases develop in the setting of background cirrhosis, and its etiopathogenesis helps select appropriate diagnostic tests and treatments.
Abstract: Since the 1970s, the epidemic of hepatocellular carcinoma (HCC) has spread beyond the Eastern Asian predominance and has been increasing in Northern hemisphere, especially in the United States (US) and Western Europe. It occurs more commonly in males in the fourth and fifth decades of life. Among all cancers, HCC is one of the fastest growing causes of death in the US and poses a significant economic burden on healthcare. Chronic liver disease due to hepatitis B virus or hepatitis C virus and alcohol accounts for the majority of HCC cases. Incidence of nonalcoholic fatty liver disease has been on the risem and it has also been associated with the development of HCC. Its pathogenesis varies based on the underlying etiological factor although majority of cases develop in the setting of background cirrhosis. Carcinogenesis of HCC includes angiogenesis, chronic inflammation, and tumor macroenvironment and microenvironment. There is a significant role of both intrinsic genetic risk factors and extrinsic influences such as alcohol or viral infections that lead to the development of HCC. Understanding its etiopathogenesis helps select appropriate diagnostic tests and treatments.
593 citations
••
TL;DR: This study expands on previous meta-analyses of the neuroanatomy of schizophrenia by elucidating a series of brain networks disrupted by the illness by performing a voxelwise, coordinate-based meta-analysis.
593 citations
••
Northwestern University1, American Society of Clinical Oncology2, New York University3, Memorial Sloan Kettering Cancer Center4, University of North Carolina at Chapel Hill5, University of Pennsylvania6, University of Texas MD Anderson Cancer Center7, Georgetown University8, Christiana Care Health System9, University of Chicago10, University of Utah11, University of Texas Health Science Center at San Antonio12, Washington University in St. Louis13
TL;DR: Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology represents the invaluable contributions of thousands of patients who participate in clinical trials and the scientists who conduct basic and clinical research.
Abstract: A MESSAGE FROM ASCO'S PRESIDENT I remember when ASCO first conceived of publishing an annual report on the most transformative research occurring in cancer care. Thirteen reports later, the progress we have chronicled is remarkable, and this year is no different. The research featured in ASCO's Clinical Cancer Advances 2018 report underscores the impressive gains in our understanding of cancer and in our ability to tailor treatments to tumors' genetic makeup. The ASCO 2018 Advance of the Year, adoptive cell immunotherapy, allows clinicians to genetically reprogram patients' own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR) T-cell therapy-a type of adoptive cell immunotherapy-has led to remarkable results in young patients with acute lymphoblastic leukemia (ALL) and in adults with lymphoma and multiple myeloma. Researchers are also exploring this approach in other types of cancer. This advance would not be possible without robust federal investment in cancer research. The first clinical trial of CAR T-cell therapy in children with ALL was funded, in part, by grants from the National Cancer Institute (NCI), and researchers at the NCI Center for Cancer Research were the first to report on possible CAR T-cell therapy for multiple myeloma. These discoveries follow decades of prior research on immunology and cancer biology, much of which was supported by federal dollars. In fact, many advances that are highlighted in the 2018 Clinical Cancer Advances report were made possible thanks to our nation's support for biomedical research. Funding from the US National Institutes of Health and the NCI helps researchers pursue critical patient care questions and addresses vital, unmet needs that private industry has little incentive to take on. Federally supported cancer research generates the biomedical innovations that fuel the development and availability of new and improved treatments for patients. We need sustained federal research investment to accelerate the discovery of the next generation of cancer treatments. Another major trend in this year's report is progress in precision medicine approaches to treat cancer. Although precision medicine offers promise to people with cancer and their families, that promise is only as good as our ability to make these treatments available to all patients. My presidential theme, "Delivering Discoveries: Expanding the Reach of Precision Medicine," focuses on tackling this formidable challenge so that new targeted therapies are accessible to anyone who faces a cancer diagnosis. By improving access to high-quality care, harnessing big data on patient outcomes from across the globe, and pursuing innovative clinical trials, I am optimistic that we will speed the delivery of these most promising treatments to more patients. Sincerely, Bruce E. Johnson, FASCO ASCO President, 2017 to 2018.
592 citations
••
TL;DR: A brief overview of the epidemiology, symptoms, and routes of transmission of this novel infection is provided and specific recommendations for dental practice are suggested for patient screening, infection control strategies, and patient management protocol.
591 citations
••
TL;DR: The potential application of pulmonary drug delivery of nanoparticles to the lungs, specifically in context of published results reported on nanomaterials in environmental epidemiology and toxicology is reviewed in this paper.
591 citations
Authors
Showing all 28104 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ralph B. D'Agostino | 226 | 1287 | 229636 |
Yi Chen | 217 | 4342 | 293080 |
Joseph L. Goldstein | 207 | 556 | 149527 |
Ronald Klein | 194 | 1305 | 149140 |
Thomas C. Südhof | 191 | 653 | 118007 |
Gordon B. Mills | 187 | 1273 | 186451 |
Scott M. Grundy | 187 | 841 | 231821 |
Michael S. Brown | 185 | 422 | 123723 |
Eric Boerwinkle | 183 | 1321 | 170971 |
Didier Raoult | 173 | 3267 | 153016 |
Russel J. Reiter | 169 | 1646 | 121010 |
Nahum Sonenberg | 167 | 647 | 104053 |
Steven N. Blair | 165 | 879 | 132929 |
Nora D. Volkow | 165 | 958 | 107463 |
Stephen J. Elledge | 162 | 406 | 112878 |